PMCB

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended October 31, 2009, for Nuvilex, Inc. (formerly eFoodSafety.com, Inc.). The Company is a smaller reporting company incorporated in Nevada. Its business strategy has shifted from food safety to developing and marketing health and wellness products, including nutritional supplements (Cinnergen, Cinnechol), scar reduction cream (Talsyn), and tattoo inks (Infinitink). The Company is currently in an early revenue stage with significant operational losses.

Key Financial Metrics

Note: Working Capital is calculated as Current Assets ($349,172) minus Current Liabilities ($1,135,577). The filing text explicitly states a working capital deficit of $814,153 in Note 2, which may reflect adjustments not immediately visible in the face of the balance sheet provided.

Material Changes vs. Prior Period

• Revenue Decline: Revenues for the six months ended October 31, 2009, dropped to $138,118 from $449,656 in the prior year period. This 69% decline is attributed to terminated retail contracts for the Cinnergen product and strategic price reductions on Cinnergen and Talsyn products.
• Increased R&D Expenses: Research and development costs surged to $441,428 for the six-month period compared to $10,898 in the prior year, driven by the development of new products like Cinnsational! and Prevorex.
• Cash Position: Cash on hand plummeted from $603,727 at the end of the fiscal year (April 30, 2009) to $9,228 as of October 31, 2009, due to operating losses and capital expenditures.
• Loan Settlement Loss: The Company recorded a $55,000 loss on the settlement of a loan receivable from Diamond Ranch Foods, Ltd., accepting a lump sum of $35,000 to cancel a $90,000 note.

Guidance, Outlook, Risks, and Contingencies

Management Commentary and Strategy

Management outlines a five-part strategy to achieve viability: (1) improving marketing for existing products and discontinuing poor performers; (2) launching new products (Cinnsational!, Prevorex); (3) cost containment, including selling the Cherry Hill facility and reducing headcount; (4) out-licensing intellectual property (negotiations with DuPont/Dow for Oraphyte); and (5) securing additional debt or equity financing.

Going Concern Warning

The filing explicitly states that the Company has not established an ongoing source of revenues sufficient to cover operating costs. With an accumulated deficit exceeding $30 million and a working capital deficit, there is substantial doubt about the Company's ability to continue as a going concern. Continued operations depend on raising additional capital.

Risks and Contingencies

• Litigation: A former executive, Kurt Mussina, has sued the Company and its subsidiaries seeking approximately $175,000 in severance. The Company disputes the claim.
• Financing Needs: The Company is actively seeking a $3.0 million convertible debt financing but is investigating more competitive terms. Failure to secure funding could halt operations.
• Internal Controls: Management concluded that disclosure controls and procedures were not adequately effective as of October 31, 2009, and are in the process of implementing corrective measures.

Investor Verification Checklist

• Liquidity Runway: Verify the Company's ability to operate with only $9,228 in cash and a working capital deficit of over $780,000.
• Financing Status: Confirm the status of the proposed $3.0 million convertible debt financing and any new equity raises.
• Facility Disposal: Monitor progress on the sale or lease of the Cherry Hill facility, estimated at $1.25 million, which is critical for cost reduction.
• Legal Exposure: Track the outcome of the Mussina lawsuit regarding the $175,000 severance claim.
• Revenue Sustainability: Assess whether the new marketing campaigns for Cinnsational! and price adjustments can reverse the 69% revenue decline.